Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer.
Fountzilas E, Kotoula V, Tikas I, Manousou K, Papadopoulou K, Poulios C, Karavasilis V, Efstratiou I, Pectasides D, Papaparaskeva K, Varthalitis I, Christodoulou C, Papatsibas G, Chrisafi S, Glantzounis GK, Psyrri A, Aravantinos G, Koliou GA, Koukoulis GK, Pentheroudakis GE, Fountzilas G. Fountzilas E, et al. Among authors: varthalitis i. Oncotarget. 2018 Nov 2;9(86):35623-35638. doi: 10.18632/oncotarget.26256. eCollection 2018 Nov 2. Oncotarget. 2018. PMID: 30479693 Free PMC article.
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study.
Briasoulis E, Fountzilas G, Bamias A, Dimopoulos MA, Xiros N, Aravantinos G, Samantas E, Kalofonos H, Makatsoris T, Mylonakis N, Papakostas P, Skarlos D, Varthalitis I, Pavlidis N. Briasoulis E, et al. Among authors: varthalitis i. Cancer Chemother Pharmacol. 2008 Jul;62(2):277-84. doi: 10.1007/s00280-007-0604-7. Epub 2007 Sep 28. Cancer Chemother Pharmacol. 2008. PMID: 17901952 Clinical Trial.
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, Pectasides D, Samantas E, Bafaloukos D, Stathopoulos GP, Karina M, Papadimitriou C, Skarlos D, Pisanidis N, Papakostas P, Markopoulos C, Tzorakoeleftherakis E, Dimitrakakis K, Makrantonakis P, Xiros N, Polichronis A, Varthalitis I, Karanikiotis C, Dimopoulos AM; Hellenic Cooperative Oncology Group. Fountzilas G, et al. Among authors: varthalitis i. Ann Oncol. 2008 May;19(5):853-60. doi: 10.1093/annonc/mdm539. Epub 2007 Nov 27. Ann Oncol. 2008. PMID: 18042835 Free article. Clinical Trial.
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
Kalofonos HP, Papakostas P, Makatsoris T, Papamichael D, Vourli G, Xanthakis I, Aravantinos G, Papadimitriou C, Pentheroudakis G, Varthalitis I, Samelis G, Syrigos KN, Xiros N, Stavropoulos M, Kosmidis P, Christodoulou C, Linardou H, Skondra M, Pectasides D, Economopoulos T, Fountzilas G. Kalofonos HP, et al. Among authors: varthalitis i. Anticancer Res. 2010 Oct;30(10):4325-33. Anticancer Res. 2010. PMID: 21036759 Clinical Trial.
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I, Fostira F, Sgouros J, Briasoulis E, Bournakis E, Bafaloukos D, Bompolaki I, Galani E, Kalogeras KT, Pectasides D, Fountzilas G, Kalofonos HP. Koutras AK, et al. Among authors: varthalitis i. Pharmacogenomics J. 2012 Dec;12(6):468-75. doi: 10.1038/tpj.2011.37. Epub 2011 Aug 16. Pharmacogenomics J. 2012. PMID: 21844885 Clinical Trial.
Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study.
Pectasides D, Papaxoinis G, Kotoula V, Fountzilas H, Korantzis I, Koutras A, Dimopoulos AM, Papakostas P, Aravantinos G, Varthalitis I, Kosmidis P, Skarlos D, Bournakis E, Bafaloukos D, Kalofonos HP, Kalogeras KT, Fountzilas G. Pectasides D, et al. Among authors: varthalitis i. Oncol Rep. 2012 Jan;27(1):216-24. doi: 10.3892/or.2011.1504. Epub 2011 Oct 13. Oncol Rep. 2012. PMID: 22025320 Clinical Trial.
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
Pectasides D, Papaxoinis G, Kalogeras KT, Eleftheraki AG, Xanthakis I, Makatsoris T, Samantas E, Varthalitis I, Papakostas P, Nikitas N, Papandreou CN, Pentheroudakis G, Timotheadou E, Koutras A, Sgouros J, Bafaloukos D, Klouvas G, Economopoulos T, Syrigos KN, Fountzilas G. Pectasides D, et al. Among authors: varthalitis i. BMC Cancer. 2012 Jun 29;12:271. doi: 10.1186/1471-2407-12-271. BMC Cancer. 2012. PMID: 22748098 Free PMC article. Clinical Trial.
A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG).
Pentheroudakis G, Kotoula V, Fountzilas E, Kouvatseas G, Basdanis G, Xanthakis I, Makatsoris T, Charalambous E, Papamichael D, Samantas E, Papakostas P, Bafaloukos D, Razis E, Christodoulou C, Varthalitis I, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Among authors: varthalitis i. BMC Cancer. 2014 Feb 20;14:111. doi: 10.1186/1471-2407-14-111. BMC Cancer. 2014. PMID: 24555920 Free PMC article.
56 results